Alie Basma

Alie Basma currently serves as the Senior Director of Safety Evaluation and Risk Management in Early Phase/Cell & Gene Therapy for Oncology at GSK, a position held since August 2022. Prior to this role, Alie Basma worked at AstraZeneca from February 2002 to August 2022, where responsibilities included serving as the Director/Principal Patient Safety Scientist in Global Patient Safety, focusing on the drug IMFINZI. Alie Basma also held positions as an Associate Director/Principal Pharmacovigilance Scientist and Senior Scientist/Team Leader in Oncology Therapeutic Area, overseeing safety signal generation and analysis for various products. Educational qualifications include a Bachelor of Science (BSc) Honours in Pharmacology and a Master of Philosophy (MPhil) in Biochemical Pharmacology from the University of Portsmouth, as well as an MBA in General from Wilmington University.